Putting Science to Work


  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2007
  • 2003
  • 2001
  • 2000
  • 1999
  • 1998
  • 1994


  • Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Centre for Advanced Protein Studies (CAPS)


  • Signed R&D Agreement with GSK to advance drug discovery in multiple therapeutic areas

  • Received PMDA Accreditation

  • Syngene Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services

  • Syngene Expands Collaboration with Baxter till 2024


  • Strategic collaboration with Zoetis to development and manufacture animal medicines

  • Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.

  • Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.

  • Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.


  • Acquisition of Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expansion into Bioinformatics & NGS Services

  • Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC), our fourth dedicated R&D center.

  • Crossed an annual turnover of rupees 10,000 Millions .


  • Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India.

  • CIL was amalgamated with Syngene.


  • Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D centre till 2020.

  • Acceptance of manufacturing facility by the Department of Health & Human Services, FDA.

  • Established a 75,000 sq.ft centre to provide stability and analytical services.


  • Crossed an annual turnover of over Rs 5,000 million in Financial Year 2013.

  • Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D centre.

  • Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.


  • Abbott and Syngene collaborated to establish Abbott's nutrition research and development centre in India and our second R&D centre.

  • Certification of clinical facilities by ANVISA.

  • Acquired 100% stake in Clinigene International Limited from Biocon.


  • Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.


  • Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health and Human Services, FDA.

  • Initiated operations in formulation development.


  • Dupont Crop Protection and our Company extended a partnership for R&D services.

  • Expansion of manufacturing services with a new plant which is cGMP compliant.


    Initiated operations in safety assessment and large molecules development services.



    Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Centre

  • Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.

  • Crossed an annual turnover of over `1,000 million in Financial Year 2007.


  • Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.  


  • Forayed into chemical development with a dedicated manufacturing facility.


  • Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.


  • First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.


  • Granted 100% Export Oriented Unit (EOU) status by the Government of India


  • Initiated operations as a CRO with services in chemistry and biology

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget